| 20.67 -1.83 (-8.13%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 26.31  |
1-year : | 30.73 |
| Resists | First : | 22.53 |
Second : | 26.31 |
| Pivot price | 17.55 |
|||
| Supports | First : | 18.12 |
Second : | 15.39 |
| MAs | MA(5) : | 20.3 |
MA(20) : | 17.98 |
| MA(100) : | 23.37 |
MA(250) : | 13.4 |
|
| MACD | MACD : | -0.5 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 88.5 |
D(3) : | 78.6 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 41.72 | Low : | 2.18 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BNR ] has closed below upper band by 13.4%. Bollinger Bands are 22.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.02 - 22.13 | 22.13 - 22.2 |
| Low: | 20.41 - 20.56 | 20.56 - 20.65 |
| Close: | 20.47 - 20.68 | 20.68 - 20.82 |
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Thu, 16 Apr 2026
Price-Driven Insight from (BNR) for Rule-Based Strategy - Stock Traders Daily
Thu, 02 Apr 2026
Burning Rock Announces Founder’s Purchase of Its ADSs - GlobeNewswire
Thu, 02 Apr 2026
Burning Rock CEO purchases $546,604 in company shares - Investing.com
Thu, 02 Apr 2026
Insider Buying: Yusheng Han Acquires Shares of Burning Rock Biot - GuruFocus
Thu, 02 Apr 2026
Burning Rock Biotech (NASDAQ:BNR) Director Purchases $5,466,143.20 in Stock - MarketBeat
Thu, 02 Apr 2026
Director Han Yusheng adds 314,870 Burning Rock Biotech (BNR) shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 9 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 45.2 (%) |
| Shares Short | 65 (K) |
| Shares Short P.Month | 77 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.38 |
| Profit Margin | -10.3 % |
| Operating Margin | -9.6 % |
| Return on Assets (ttm) | -4.1 % |
| Return on Equity (ttm) | -10 % |
| Qtrly Rev. Growth | 0.2 % |
| Gross Profit (p.s.) | 44.61 |
| Sales Per Share | 59.75 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -27.94 |
| PEG Ratio | 0 |
| Price to Book value | 2.79 |
| Price to Sales | 0.34 |
| Price to Cash Flow | -6.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|